Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

• Status: NOT_YET_RECRUITING
• Trial end date: 2035-09-01

Summary

This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.

• Phase: PHASE2

Details

• Lead Sponsor: Children's Oncology Group
• Treatments: Asparaginase; auricularum; Biopsy; Bortezomib; calaspargase pegol; Calcium Dobesilate; Cyclophosphamide; Cytarabine; daratumumab; Daunorubicin; deltacortene; Dexamethasone; dexamethasone 21-phosphate; dexamethasone acetate; Doxorubicin; exifone; High-Energy Shock Waves; Hydrocortisone; Magnetic Resonance Spectroscopy; Medrol Veriderm; Mercaptopurine; merphos; Methotrexate; Methylprednisolone; nelarabine; pegaspargase; Prednisolone; Prednisone; prednylidene; Radiation; Radiotherapy; Specimen Handling; Spinal Puncture; Thioguanine; Vincristine